Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

A modified FLOT regimen (fluorouracil, oxaliplatin, and docetaxel; TFOX) outperformed a standard chemotherapy triplet for the ...

Daiichi Sankyo’s corporate officer and general counsel in a statement. First cleared as a later-line therapy for HER2-positive breast cancer in 2019, Enhertu has expanded into earlier use ...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer. Delytact ...

In the rapidly evolving landscape of oncology, precision is the cornerstone of progress. A leading biopharmaceutical company specializing in ...